Download PDF
Homeopathy 2004; 93(02): 84-87
DOI: 10.1016/j.homp.2004.02.006
Original Paper
Copyright © The Faculty of Homeopathy 2004

Anti-inflammatory activity of Arnica montana 6cH: preclinical study in animals

S.B Macêdo
1   Faculdade de Odontologia, Pontifı́cia Universidade Católica de Brası́lia, Brası́lia, Brazil
,
L.R Ferreira
2   Instituto de Med. Veterinária, Campus Poços de Caldas, Pontifı́cia Universidade Católica de Poços de Caldas, Minas Gerais, Brazil
,
F.F Perazzo
3   Laboratório de Fitofármacos, Universidade de Alfenas, Rod. MG 179, km 0, CP 23, CEP 37130-000, Alfenas, Minas Gerais, Brazil
,
J.C Tavares Carvalho
3   Laboratório de Fitofármacos, Universidade de Alfenas, Rod. MG 179, km 0, CP 23, CEP 37130-000, Alfenas, Minas Gerais, Brazil
4   Faculdade de Ciências da Saúde de São Paulo (FACIS-IBEHE), S. Paulo, Brazil
› Author Affiliations
Subject Editor:
Further Information

Publication History

Received04 March 2003
revised03 June 2003

accepted22 January 2004

Publication Date:
19 December 2017 (online)

    Permissions and Reprints

Abstract

The anti-inflammatory effect of Arnica montana 6cH was evaluated using acute and chronic inflammation models. In the acute, model, carrageenin-induced rat paw oedema, the group treated with Arnica montana 6cH showed 30% inhibition compared to control (P<0.05). Treatment with Arnica 6cH, 30 min prior to carrageenin, did not produce any inhibition of the inflammatory process. In the chronic model, Nystatin-induced oedema, the group treated 3 days previously with Arnica montana 6cH had reduced inflammation 6 h after the inflammatory agent was applied (P<0.05). When treatment was given 6 h after Nystatin treatment, there was no significant inhibitory effect. In a model based on histamine-induced increase of vascular permeability, pretreatment with Arnica montana 6cH blocked the action of histamine in increasing vascular permeability.

Keywords

Arnica montana 6 cH - anti-inflammatory activity - preclinical
 

  • References

  • 1 Gibson DM. Arnica, a study. Br Hom J 1972; 61: 167–170.
    PubMed
  • 2 Tetau M. Matéria Médica Homeopática—Clı́nica e Associações Bioterápicas. Organização Andrei Ltda., S. Paulo, Brazil 1987, pp 67–69.
    PubMed
  • 3 Edward H. Arnica montana. The Flora Homoeopathic. New Delhi: B. Jain Publishers, 1988, pp 36–44.
    PubMed
  • 4 Blackwood AL. Matéria Médica, Terapeutica y Farmacologia Homeopática. International Homeophatic Medical Organization, 3a edição, Mexico: B. J. Publishires Ltda., 1990, pp 143–144.
    PubMed
  • 5 Tyler ML. Retratos de Medicamentos Homeopáticos. Livraria e Editora Santos S. Paulo, Brazil 1992, pp 92–99.
    PubMed
  • 6 Bucay JW. Algumas notas sobre la planta medicinal Arnica montana L. Rev Med Inst Mex Seg Soc 1995; 33(3): 312–326.
    PubMed
  • 7 Wagner VH. Immunstimulierend wirkende Polysacchaide (Heteroglykane) aus höheren Pflanzen. Arzneimittel Forschung 1984; 34(6): 659–661; 1985; 35(7): 1069–1075.
    PubMed
  • 8 Wagner H, Jurcic K. Immunologische untersuchungen von pflanzlichen kombinationspräparaten. Neimittelforschung 1991; 41(10): 1072–1076.
    PubMed
  • 9 Puhlmann J, Zenk MH, Wagner H. Immunologically active polysaccharides of Arnica montana cell cultures. Phytochemistry 1991; 30(4): 1141–1145.
    PubMed
  • 10 Schröder H. Helenalin an 11,13-dihydrohelenalin, two constituents from Arnica montana L., inhibit human platelet function via thiol-dependent pathways. Thromb Res 1990; 57: 839–845.
    PubMed
  • 11 Quezada RM. Coloquio de farmacodinamica homeopatica. Arnica Montana. La Homeop Mexico 1987; 507: 13–17.
    PubMed
  • 12 Farmacopéia Homeopática Brasileira, S. Paulo: Editora Andrei, 1977, 115pp.
    PubMed
  • 13 Mustard JF, Movat JZ, Macmorine DRL, Senyi A. Release of permeability factors from blood platelet. Proc Soc Exp Biol Med 1965; 119: 981–988.
    PubMed
  • 14 Lykbe AMJ, Cummings R. Inflammation in healing. 1. Time- course and medition of exudation in wound healing in the rat. Brit J Exp Pathol 1969; 50: 309–318.
    PubMed
  • 15 Di Rosa M, Willoughby DA. Screens for anti-inflammatory drugs. J Pharm Pharmcol 1971; 23: 297–298.
    PubMed
  • 16 Schiatti P, Selva D, Arrigoni-Martelli E. L’edema localizzato da nystatin come modello di inflammazione sperimentale. Boll Chim Farm 1970; 109: 33–38.
    PubMed
  • 17 Trowbridge HO, Emling RC. Mediadores quı́micos da resposta vascular. Inflamação uma revisão do processo, Vol 27–42. S. Paulo: Quintessence Publishing Co. Inc., 1996, 172p.
    PubMed
  • 18 Carmine TC. Effects of high potencies of tumour necrosis factor alpha on H20 production in cultured neuroblastoma cells by enhanced luminol-dependent chemiluminescence (ECL). A possible system for investigating the biological significance of homoeopathic high potencies. Br Hom J 1997; 86: 67–72.
    PubMed